acute lymphoblastic leukemia (ALL) at diagnosis), 2 with adult T-cell leukemia (ATL) and 3 with chronic myelogenous leukemia (CML), from 6 patients with acute infection and from 37 normal volunteers. The profile with acute leukemia was classified according to the criteria developed b y t h e F r e n c h -A m e r i c a n -B r i t i s h ( FA B ) Cooperative Group.
Mononuclear cells were isolated from bone marrow or blood by using Ficoll Isopaque method and used for the evaluation of STC-1 mRNA.
Study protocols were approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis at Tohoku University. All patients and healthy volunteers gave informed consent.
Nested RT-PCR
One microgram of total RNA was used for the synthesis of cDNA in a 20 μ l reaction mixture containing 0.5 μ g oligo(dt), 200 units of murine l e u k e m i a v i r u s r e v e r s e t r a n s c r i p t a s e (Superscript TM : GIBCO-BRL, Gaithersburg, MD, USA), 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl 2 , 0.5 mM of each dNTP and 10 mM DTT. The reaction mixture was incubated at 42°C for 50 minutes, heated at 70°C for 15 minutes, and stored at −20°C until use. The sequences of primers for two-step PCR of STC-1 (GenBank accession number NM003155) were as follows; forward primer (201-235) 5´-CTTCACT CAAGCCAGGAGAGGGAAA-3´; outer reverse primer (1063-1090) 5´-TGGTGTGTCAACACC CCTAAAATGATA-3´; internal forward primer (374-407) 5´-GTGGCGGCCCAAAACTCAGCT GAA-3´; internal reverse primer (1003-1028) 5´-TTATGCACTCTCATGGGATGTGCGTT-3´.
The reaction mixture for first PCR was in a final volume of 50 μ l including 2 μ l of cDNA, 2.5 U of Taq DNA polymerase (Toyobo, Tokyo), 1× PCR buffer (10 mM Tris-HCl (pH 8.3), 50 mM KCl), 1.5 mM MgCl 2 , 0.2 mM dNTP, and 0.5 mM of each primers. This mixture were subjected to each 25 cycles of amplification under 94°C for 1 minute, 65°C for 2 minutes, and 72°C for 3 minlem as a predictive marker for MRD in acute leukemia (Schmid et al. 1997; Elmaagacil et al. 2000) .
Stanniocalcin 1(STC-1) is a glycoprotein hormone that regulates blood calcium levels in fish. The sequence similarity of STC-1 to its fish counterparts suggests that human homologue, STC-1, regulates calcium and phosphate homeostasis in the kidney and intestine (Chang et al. 1996a, b; Wagner et al. 1997; Koide et al. 1998; Madsen et al. 1998; Varghese et al. 1998 ). Human STC-1 mRNA is, however, expressed in multiple tissues, suggesting that human STC-1 might have additional functions, for example, neural cell differentiation (Zhang et al. 1998) , bone formation (Yoshiko et al. 1998; Stasko et al. 2001) . Of note, its expression is observed in malignant tissues such as adrenal tumor, hepatocellular carcinoma and breast cancer, suggesting some roles in transformed cells (Lal et al. 2001; Miura et al. 2000; Wascher et al. 2003) .
In this study, we show the clinical importance of the detection of STC-1 mRNA, especially in association with MRD of human leukemia. 
MATERIALS AND METHODS

Cell lines
Patients and samples
We analyzed 168 bone marrow (BM) samples and 312 peripheral blood (PB) samples from 59 adult patients with acute leukaemia (34 with acute myelogenous leukemia (AML), 19 with utes by using a DNA thermal cycler (Astec PC-700, Fukuoka). The second PCR were performed in the same procedure as the first PCR using 2 μ l of the first-round products as a template. The second amplified PCR products were electrophoresed on 1.5% agarose gel and confirmed with UV light as a single band of 645 bp by staining with ethidium bromide. The presence of intact RNA and adequate cDNA generation was evaluated for each sample by a control PCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequence-specific primer (Clontech, Palo Alto, CA, USA), which amplifies a 983 bp fragment.
Real-time quantitative RT-PCR
Quantitative RT-PCR was performed according to the procedure as described previously (Fujimaki et al. 2000 ) using a TaqMan EZ RT-PCR kit (Perkin Elmar, Foster City, CA, USA). For RT-PCR 1 μ g of total RNA sample was added to a 50 μ l amplification reaction solution containing 1×TaqMan EZ buffer, 4 mM magnesium acetate, 200 μ M of dATP, dCTP, and dGTP, 400 μ M dUTP, 0.75 units rTth DNA polymerase, 0.5 U AmpErase uracil N-glycosylase, 200 nM of each primer, and 100 nM of TaqMan probe. The thermal cycling conditions included 2 minutes at 50°C, 30 minutes at 60°C (RT reaction) and 10 minutes at 95°C. Thermal cycling proceeded with 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. All reactions were performed in the ABI PRISM TM 7700 Sequence Detection Systems (Perkin Elmar). Those for an amplification as a control gene included a TaqMan GAPDH Control Reagent (Perkin Elmar). The sequence of primers and probe for STC-1 were as follows; forward primer (705-723) 5´-AACCCTGAAGCCA TCACTG-3´; reverse primer (761-782) 5´-GCTTCGGACAAGTCTGTTATAG-3´ and probe (733-756) 5´-AGCTGCCCAATCACTTCTCCA ACA-3´.
The probe was labeled with fluorescent FAM (reporter) at the 5´ end and fluorescent TAMRA (quencher) at the 3´ end. The parameter C t (threshold cycle) was defined as the fractional cycle number at which the reporter fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. To establish a standard curve, standard RNAs were synthesized by in vitro transcription. Briefly, STC-1 cDNA was amplified by PCR using reverse-transcribed total RNA of K562 cells, purified using a Qiagen PCR purification kit (Qiagen, Valencia, CA, USA), and cloned into the Not I (Takara, Kyoto) site of pGEM-T expression vector (Promega, Madison, WI, USA). After the sequence was verified, the plasmids were linearized and transcribed by T7 RNA polymerase (Roche, Indianapolis, IN, USA). By using a serial dilution of standard RNA, the standard curve was produced from the linear relationship between the C t value and the logarithm of the copy numbers. The absolute copy numbers of STC-1 in the samples were calculated by Ct using a standard curve, and the results were standardized by copy numbers of GAPDH.
RESULTS AND DISCUSSION
To know the clinical significance to detect STC-1 mRNA in vivo, we first studied if STC-1 mRNA is detected in mononuclear cells (MNC) from peripheral blood. Nested RT-PCR failed to detect STC-1 mRNA in peripheral blood from normal subjects, but the transcripts were delected in PHA-activated T cells (Fig. 1A) . The expression of STC-1 mRNA was also found in myeloid cell lines, T cell lines and erythroid cell lines, but not in HL60 and Raji cell lines (Fig. 1B) . Further, STC-1 mRNA was observed in MNC of blood from patients with leukemia (Fig. 2) . This led us to hypothesize that STC-1 mRNA may be detected in the growing cells, especially in leukemia cells, and we proceeded to study with clinical samples.
The results using clinical samples showed that the transcripts were positive in 24 of 26 BM samples and in 12 of 13 blood samples from patients with acute leukemia. The transcripts were also detected in 2 of 2 BM samples, but not in 28 blood samples from normal subjects. To measure the amount of STC-1 transcripts, we, then, developed a quantitative assay by using real-time RT-PCR. STC-1 transcripts were detectable at least at 2.5×10 1 copies of synthetic STC-1 RNA that was prepared as a control. Linearity was obtained from 2.5×10 1 to 2.5×10 5 copies. The standard curve showed a good correlation between the copies of STC-1 RNA and C t (r=0.9999). The coefficient of variation in STC-1 transcripts by this system was approximately 20% during the assay. GAPDH transcripts were detected in 10fg of synthetic RNA (6.4×10 3 copies) as an internal control. Linearity was from 6.4×10 3 to 6.4×10 8 copies. The number of copies was standardized by the ratio of copy number of STC-1 to that of GAPDH in each sample. MNC of blood from healthy donors were first examined for the copy number of STC-1 transcripts by the system. The cut-off value (46 copies) was calculated by means+2SD of copy numbers of PB from healthy donors (n=37). We tried to apply this system to detect MRD of acute leukemia in vivo.
The levels of STC-1 mRNA in five patients with infectious disease and in 37 normal subjects were within the cut-off levels. On the other hand, levels of STC-1 mRNA in peripheral bloods increased in 8 (23.5%) of 34 patients with AML, in 1 (9.1%) of 11 patients with B-ALL, in 4 (50%) of 8 patients with T-ALL and in 2 (100%) of 2 patients with ATL at diagnosis or at relapse (Fig. 3) . Increased levels of STC-1 mRNA were not found in three patients with CML even at B lymphoid blastic crisis. The levels of STC-1 mRNA in 38 patients, who were within the normal range at diagnosis and relapse, were also below the cut-off levels at complete remission (CR), irrespective of their clinical condition including the presence of infection. We could have a follow up study in 7 patients, who showed the increased levels of STC-1 mRNA at diagnosis or at relapse. Among them, 6 patients including Figs. 4A-4C showed rapidly decrease of STC-1 transcripts untill below the cut-off value after treatment corresponding to the clinical improvement, whereas the level of STC-1 mRNA was still high in the remaining one (Fig. 4H ), in whom chemotherapy was unsuccessful. This indicates the levels of STC 1 mRNA may correspond to the numbers of leukemia cells. Table1 also shows the relationship between the expression levels of STC-1 mRNA and the prognosis in patients at CR. Seven patients showed an increased level of the transcripts at CR, and all of them relapsed 1-4 months after the evaluation of STC-1 mRNA. Clinical course of 5 representative cases in this group is shown in Fig. 4D -H. There is a paper describing that STC-1 mRNA is undetectable in bone marrow samples (Wascher et al. 2003 ), but we could detect STC-1 mRNA in bone marrow samples. This may be attributed to the difference of the primers used for the amplification, and indicate that our detection system is sensitive enough to evaluate the levels Fig. 3 . Quantitative analysis of STC-1 mRNA in peripheral blood from patients with leukemia by using real-time PCR methods. The copy numbers of STC-1 mRNA in peripheral blood normalized by the copy numbers of GAP-DH were shown. The stages of leukemia are classified at diagnosis or relapse and at complete remission (CR). of STC-1 mRNA in vivo. We did not, however, directly show the presence of STC-1 mRNA in leukemia cells, and, therefore one may argue whether STC mRNA is a marker as a MRD in leukemia. However, a variety of leukemia cell lines and PHA-stimulated T cells expressed STC-1 mRNA, and clinical study demonstrating a close association between the blast numbers and the elevated levels of STC-1 mRNA, supports the usefulness of STC-1 mRNA as a marker of MRD in some types of leukemia, although we cannot still deny a possibility the participation of stroma cells or cytokine-producing cells at this evaluation. Taken together, these results indicate that low amounts of transcripts after treatment seem to predict a good outcome, but an increase in transcripts at CR may indicate a high risk of a relapse into leukemia. Although the frequency of the increase in STC-1 mRNA was not high at the diagnosis and at relapse compared with other MRD markers, such as WT1, the STC-1 was positive not only in AML patients, but also in T-ALL patients that may be less frequently positive for WT-1. Further studies of a long-term follow-up of many patients with leukemia are necessary to establish the usefulness of monitoring STC-1 expression levels for an early diagnosis of a relapse into acute leukemia.
